For research use only. Not for therapeutic Use.
BMS-911172 (Cat No.: I045557) is a selective small-molecule Aurora B kinase inhibitor developed by Bristol-Myers Squibb for oncology research. By inhibiting Aurora B, a key regulator of chromosome segregation and cytokinesis, BMS-911172 disrupts mitotic progression, leading to cell cycle arrest and apoptosis in proliferating cancer cells. It has been evaluated in preclinical and clinical studies for its potential in treating hematological malignancies and solid tumors. BMS-911172 serves as a valuable tool for investigating mitotic control, kinase signaling, and anticancer therapeutic strategies.
| CAS Number | 1644248-18-9 |
| Synonyms | (2R)-2-amino-N-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide |
| Molecular Formula | C16H19F2N3O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C16H19F2N3O3/c1-9(2)5-12(19)15(22)21-10-3-4-11(14-7-20-8-23-14)13(6-10)24-16(17)18/h3-4,6-9,12,16H,5,19H2,1-2H3,(H,21,22)/t12-/m1/s1 |
| InChIKey | GCTFTMWXZFLTRR-GFCCVEGCSA-N |
| SMILES | CC(C)CC(C(=O)NC1=CC(=C(C=C1)C2=CN=CO2)OC(F)F)N |
| Reference | [1]. Hartz RA, et al. Aryl amide kinase inhibitors. WO2015006100A1. |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
